Boston Scientific gets deep brain stimulation CE mark; 3-D printing comes to ultra-thin materials;

@FierceMedDev: Researchers develop the first blood test to diagnose adult depression. Story | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of polio vax application. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Drug delivery specialist Genisphere receives an additional $2M in funding. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Mainstay Medical CEO reveals company's path to market for its neuromodulation implant. More | Follow @EmilyWFierce

> Boston Scientific received a CE mark for its Vercise deep brain simulation treatment device to patients with tremors. Release

> Using an electronic nose, researchers at the University of Leicester, have figured out a way to sniff out traces of infectious diseases in patients feces. News

> The cost-effective manufacturing practice of 3-D printing ultra-thin layers of material is coming soon from Northeastern University researchers. Story

Biotech News

@FierceBiotech: Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac. News | Follow @FierceBiotech

@JohnCFierce: Am I missing something? If the FDA eviscerates the low-T market, restricting use, doesn't that destroy the prospects of , Clarus, etc.? | Follow @JohnCFierce

@DamianFierce: $NVO's eye on a Seattle expansion could be balm to local biotech as Amgen heads for the door. Article | Follow @DamianFierce

@EmilyMFierce: ICYMI: Check out these 7 notable academic-pharma alliances of 2014. Feature | Follow @EmilyMFierce

> Struggling Merck KGaA plans blockbuster R&D campaign for biosimilars, pact for PD-L1. Story

> Merck's weekly diabetes drug stacks up to blockbuster Januvia in Phase III. Report

> Oral low-T drugs in the pipeline face a showdown with the FDA. More

Pharma News

@FiercePharma: Now trending on FiercePharmaMarketing: First-to-market launch? Bonus--but double bonus if you're Big Pharma. Article | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. More | Follow @EricPFierce

@CarlyHFierce: This week in FiercePharmaMarketing: Takeda lets 900 reps fly at obesity; AZ + James Van Der Beek = FluMist sales? More | Follow @CarlyHFierce

> Bayer brings $12.9B plastics spin-off to Big Pharma's slim-down party. Story

> Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds. Article

> Real-world hep C patients drop off pricey Sovaldi, CVS study finds. More

Vaccines News

> Takeda reorg preps vaccines unit for emerging markets test. News

> 10 volunteers receive Glaxo Ebola vaccine with no adverse effects yet. Story

> Merck KGaA calls it quits on cancer vaccine--again. More

> Protein Sciences nabs stake in diabetes vax developer Diamyd. Story

> AstraZeneca sends James Van Der Beek 'camping' to promote FluMist Quadrivalent. Article

Pharma Manufacturing News

> More FDA issues arise for Hospira in India. News

> Novartis says more cuts coming for New York Diovan plant. More

> FDA procedural delay on Rytary gives Impax breathing room. Report

> Baxter issues recall, this time because antibacterial gets mixed in wrong carton. Story

> Partner Sanofi wants to produce the insulin to be used in MannKind's Afrezza. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.